Trial Profile
Phase II trial of the combination of pembrolizumab and pemetrexed as first-line therapy in patients with non-squamous, non-small cell lung cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2015
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co
- 27 Jan 2015 New trial record